to-BBB appoints Anders Harfstrand as chief executive

15 September 2014

Dutch biopharma company specializing in brain diseases, to-BBB, has appointed Anders Harfstrand as chief executive.

He will be responsible for accelerating the advance of the clinical pipeline and further application of the company’s technology.

Dr Harfstrand has more than 25 years’ experience in biotech and big pharma, and joins the company from Adama Europe where he was president and chief executive. He has held high-level management positions at Humabs Biomed, Nitec Pharma (now Horizon Pharma), Serono SA, Pfizer and Pharmacia. Over his career, he has been responsible for developing and commercializing pharma brands in many global markets, and has completed corporate and fundraising deals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK